Minoryx Therapeutics is recruiting for a clinical trial focusing on cALD in Europe.
The NEXUS clinical trial is a phase 2, open-label clinical study designed to assess the efficacy and safety of leriglitazone in male pediatric patients with early stage cerebral X-linked adrenoleukodystrophy (cALD).
The NEXUS study recruits cALD patients with early cerebral MRI lesions. All patients will be receiving leriglitazone and they will be carefully monitored for safety, clinical symptoms and changes in cerebral MRI lesions. The study has been designed with input from both EMA and FDA, as well as EU and US clinical experts in X-ALD and patient advocacy groups. The study design does not interfere with the current Standard of Care and does not delay HSCT therapy if it becomes indicated.
For further information about registering visit: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000654-59